The Prognostic and Diagnostic Value of Ferritin in Critically Ill Patients With Special Focus on Underlying Hemophagocytic Lymphohistiocytosis
Study Details
Study Description
Brief Summary
Retrospective analysis of ferritin, outcome and HLH-criteria in critically ill patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
The study is a retrospective register study of critically ill patients from Charité - Universitätsmedizin Berlin during 2000 and 2016 that had at least one measurement of plasma ferritin. Outcome, underlying diagnoses and HLH-2004 criteria (Henter JI et al. 2007) will be analyzed and the HScore of these patients will be calculated (Fardet L et al. 2014). All recorded data of the specific admission term in ICU will be used for the analysis. No follow-up of the patients after discharge will be performed in this study. The study does not involve any randomization or any drug testing.
Update 2019: We expanded our database for the years until 2018 and also for the surgical and medical ICUs of the Charité - Universitätsmedizin Berlin (from 256 to 2623 patients).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Critically ill patients Male and female critically ill patients admitted to the Charité - University Medicine Berlin during 2000 and 2018. |
Outcome Measures
Primary Outcome Measures
- Mortality [Participants will be followed up for the duration of hospital stay, an expected average of two months]
A retrospective analysis of patients with available charts to determine the outcome whether patients survived the ICU or died.
- Probability of having undiagnosed Hemophagocytic lymphohistiocytosis (HLH) [The participants will be followed up for the duration of hospital stay, an expected average of two months]
Retrospective analysis of available charts, underlying diagnoses, findings and blood values: HLH-2004 criteria (Henter JI et al. 2007) and HScore (Fardet L et al. 2014)
Secondary Outcome Measures
- Diagnoses [Participants will be followed up for the duration of hospital stay, an expected average of two months]
Retrospective analysis of available charts and underlying diagnoses
- Intensive care unit stay [Participants will be followed up for the duration of intensive care unit stay, an expected average of one week]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
male and female patients
-
at least one measurement of plasma ferritin
Exclusion Criteria:
-age below 18 years
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Charite University, Berlin, Germany
Investigators
- Study Director: Claudia Spies, MD, Prof., Department of Anesthesiology and Operative Intensive Care Medicine CCM/CVK, Charité - Universitätsmedizin Berlin
Study Documents (Full-Text)
None provided.More Information
Publications
- Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014 Sep;66(9):2613-20. doi: 10.1002/art.38690.
- Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31.
- HLH